Merck & Co., Inc. Announced Q1 2026 Earnings on April 30, 2026, Reporting "revenue of $16.3 billion" for the quarter.

For the first quarter, Merck & Co., Inc. reported that "Total company revenues were $16.3 billion" representing "an increase of 5%". "Gross margin was 81.9%" for the quarter.

The company noted it "reported a loss of $1.28 per share. which includes a negative impact of $3.62 per share from the onetime charge related to Cidara". For the quarter, "Operating expenses increased to $15.2 billion, including a $9 billion onetime charge related to the acquisition of Cidara Therapeutics".Management highlighted several key business updates, noting "the transformation of our portfolio to a far more diversified set of commercial drivers is now well underway". The company is currently seeing "initial launches of over 20 new products". In terms of strategy, the company announced a "multiyear partnership with Google Cloud to scale advanced AI, data and agentic capabilities" and highlighted its "proposed acquisition of Terns Pharmaceutical" to advance "TERN-701".Regarding product announcements and performance for the quarter, "sales of the KEYTRUDA family of products which includes KEYTRUDA and KEYTRUDA QLEX, increased 8% to $8 billion". "WINREVAIR continues to have a positive impact on patients with pulmonary arterial hypertension.

Global sales were $525 million" for the quarter. "GARDASIL sales were $1.1 billion" for the quarter.

The company also announced that "the FDA approved IDVYNSO as a new treatment option for adults with virologically suppressed HIV-1".For full year 2026 forward guidance, management stated, "We now expect revenue to be between $65.8 billion and $67 billion". For the full year, "We expect EPS of $5.04 to $5.16". Furthermore, "Our gross margin assumption remains approximately 82%" and "Operating expenses are assumed to be between $36 billion and $36.8 billion".